Vertical Semiconductor | $11,000,000 | (Oct 16, 2025)
Aragorn AI | $4,300,000 | (Oct 16, 2025)
Pelage Pharmaceuticals
United States
- Los Angeles, California
- 16/10/2025
- Series B
- $120,000,000
Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing first-in-class treatments for hair loss. With a focus on stem cell biology and metabolism, Pelage is advancing a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body’s ability to naturally grow hair. Its lead program, PP405, is currently in Phase 2a clinical trials. Through its rigorous scientific foundation, Pelage is pioneering first-in-class hair growth solutions for people of all hair types experiencing hair loss.
To stay in the loop on future trials for PP405, sign up for emails at https://pelagepp405.com/
- Industry Biotechnology Research
- Website https://pelagepharma.com/
- LinkedIn https://www.linkedin.com/company/pelage-pharmaceuticals/
Related People
Daniel GilFounder
United States -
Corona del Mar, California
Led Pharmaceutical research and early stage clinical development in the areas of Ophthalmology, Neuroscience and Dermatology at Allergan. Elevated 13 drug candidates into clinical development, directed 8 clinical development teams and oversaw clinical studies ranging from translational to phase 2 proof-of-concept stages. Inventor on more than 70 issued US patents and author on 42 peer-reviewed research articles.
Planyear | $12,000,000 | (Oct 16, 2025)
OutcomesAI | $10,000,000 | (Oct 16, 2025)
Woz (YC W25) | $6,000,000 | (Oct 16, 2025)
io Health | $2,000,000 | (Oct 16, 2025)
Tubulis GmbH | $359,197,300 | (Oct 16, 2025)
Intelo.ai | $2,000,000 | (Oct 16, 2025)
Corbel | $6,700,000 | (Oct 16, 2025)
Telcoin | $25,000,000 | (Oct 16, 2025)
Viven | $35,000,000 | (Oct 16, 2025)